ArticleBiomedicines2025

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia.

Filip Marković et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.